Pricing Log in Create free account
Tuesday 20 October 2026 Export INCY’s income statement to Excel — free account

Incyte Corporation

INCY Healthcare Biotechnology

Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024. In the quarter to June 2026, revenue grew 37.7%, EPS grew 39.7%, free cash flow grew 1,829.5% and total debt fell 10.5%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years.

116.27 3.02 +2.67%
Market cap
$23.0B
P/E
13.9×
Fwd P/E
58.4×
Dividend yield
—
F-score
9/9
Altman Z
8.57
Beneish M
−2.43
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Incyte Corporation (INCY) EV/Sales

Alert me on EV/Sales

As of 19 October 2026, Incyte Corporation (INCY) trades at a EV/Sales of 3.1×. Over the past ten years it has ranged from 1.9× (April 2025) to 36.5× (September 2015); the current reading is higher than 20% of that period. That is below the Biotechnology industry median of 9.5× and below the Healthcare sector median of 3.4×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 3.1× 6.51%
FY2024 2.9× (3.61%)
FY2023 3.0× (30.00%)
FY2022 4.3× (8.30%)
FY2021 4.6× (28.01%)
FY2020 6.5× (16.56%)
FY2019 7.7× 20.38%
FY2018 6.4× (49.36%)
FY2017 12.7× (26.41%)
FY2016 17.2× (32.97%)

Quarterly newest first

Period EV/Sales Change
Jun 2026 3.1× 13.50%
Mar 2026 2.8× (9.91%)
Dec 2025 3.1× 7.51%
Sep 2025 2.8× 20.54%
42 more quarters

Against its own ten years

Low 1.9× High 36.5×
Ten-year median 6.6×
Current reading's percentile 22

EV/Sales against peers

Company EV/Sales
BNTX BioNTech SE Sponsored ADR compare 1.9×
INCY Incyte Corporation 3.1×
ALNY Alnylam Pharmaceuticals, Inc. compare 6.0×
EXEL Exelixis, Inc. compare 6.1×
GMAB Genmab A/S Sponsored ADR compare 6.6×
ASND Ascendis Pharma A/S compare 11.9×
RPRX Royalty Pharma PLC compare 13.8×
INSM Insmed, Inc. compare 17.9×
ROIV Roivant Sciences Ltd. compare 2,857×
Biotechnology industry median 9.5×
Healthcare sector median 3.4×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on INCY